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FOREWORD 
The Scientific Committee for Pesticides was set up by Commission 
Decision 78/436/EEC of 21 April 1978 (OJ No L 124 of 12.05.78, p. 16) in 
order to provide the Commission with informed opinions on scientific and 
technical matters relating to the use and marketing of pesticides and to 
their residues, particularly in food and feedingstuffs. 
The members of the Committee are independent and highly qualified in the 
fields of applied biology, toxicology, ecotoxicology and chemistry. The 
Secretariat of the Committee is provided by the Commission's 
Directorate-General for Agriculture. 
The Committee's third series of reports, published in this volume, 
relate to questions put to it by the Commission on the safety in use, 
for man and environment, of certain pesticides and on the maximum 
permitted levels of their residues in foodstuffs. Questions in this 
connection had arisen in the course of the Commission's work on the 
approximation of Member States' legislation concerning pesticides. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON CAPTAFOL, CAPTAN AND FOLPET. 
(Opinion expressed on 7 July '87) 
BAÇKGRQUND_AND_IERMS_OF_REFERENÇE 
In the context of its work to revise Annexes II of Council 
Directive 76/895/EEC and 86/362/EEC, relating respectively to the 
fixing of maximum levels for pesticide residues in and on fruit 
and vegetables and on cereals (1), the Commission invited the 
Scientific Committee for Pesticides to examine the toxicological 
data on the phthalimide fungicides captafol, captan and folpet. 
On the basis of this evaluation, the Commission reguested the 
Committee to estimate, if possible, an acceptable daily intake 
for each of the compounds and accordingly to consider the 
appropriateness or otherwise of the existing maximum residue 
levels. 
The levels provided for by Directive 76/895/EEC at the time of 
writing were: 
-1 
Maximum levels in mg/kg (ppm) 
Captafol: 8 
2 
5 
leaf vegetables 
root vegetables 
other fruit and vegetables 
Captan: 15: fruit and vegetable 
Folpet: 15: cherries, lettuce, raspberries, blue-
berries, currants, grapes, strawberries 
10: citrus fruit, pome fruit 
5: tomatoes 
2: other fruit and vegetables 
-2 
DISCUSSION 
1. CAPTAFOL 
1.1 INTRODUCTION 
The fungicide captafol has been evaluated bv the Joint 
FAO/WHO Meetings on Pesticide Residues (JMPR) in 1969, 1973 
and 1977 and an acceptable daily intake of 0.1 mg/kg (ADI) 
was established in 1977 (2). Later it became apparent that 
all the studies on which the ADI was based had been carried 
out by Industrial Bio-Test Laboratories. Therefore in 1982 
the JMPR (2) replaced the ADI by a temporary ADI of 0.01 
mg/kg b.w. and reguired a number of new studies (semichronic 
and chronic toxicity, carcinogenicity, reproduction). The 
ADI was withdrawn in 1985 by the JMPR because it was 
concluded that captafol is carcinogenic in both rats and mice 
(2). 
1.2 T0XIC0L0GIAL ASPECTS 
1.2.1 Sybçhroniç_îgxiçiiy. 
Two semichronic studies were carried out in the rat by 
different manufacturers. In the first, many toxic effects 
were found at the two highest dose levels of 2000 and 8000 
mg/kg feed, consisting of clinical signs, reduced food intake 
and growth, clinico-chemical effects and changes in organ 
weights. Histopathology revealed treatment related changes 
in kidneys, liver, skin and stomach. No effects were found 
at 500 mg/kg diet (ca. 25 mg/kg body weight (b.w.) (3). In 
the second study, growth and food consumption were decreased 
at the highest dose level of 3000 mg/kg feed and effects on 
some organ weights were also found. 
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Histopatholoqy revealed alterations in the kidneys at 1000 
and 3000 mg/kq, consistinq of tubular nephrosis in the 
males. In the females an increased incidence of focal 
nephropathy was observed. Acanthosis, hyperkeratosis and 
ulceration were present in the non-qlandulax region of the 
stomach at 3000 mq/kq. Because there was a drastic loss of 
captafol from the diets at the two lower dose levels, it is 
not possible to establish a no effect level in this 
experiment (4). 
Two chronic studies have been performed in mice. In one study 
bv a manufacturer (5, 6), dose levels of 0, 300, 1000 and 3000 
mq/kq feed were used, an increased incidence of lymphosarcomas 
and total haemanqiosarcomas was found at the hiqhest dose level 
of 3000 mq/kq feed. A number of other effects, especially at 
the hiqhest dose level, were clinical symptoms of toxicity, 
marked reduction in survival and effects on the red blood 
picture. Possiblv because of the early mortality no liver cell 
tumours were found at 3000 mq/kq and the potential development 
of neoplastic lesions in the duodenum could not be reliably 
assessed (5, 6). 
In the other study carried out by Ito et al. (7) using a 
different strain of mice and dose levels of 0, 750, 1500 and 
3000 mq/kq feed, a hiqh mortality was found especially at the 
hiqhest dose level of 3000 mq/kq. Growth was inhibited in all 
dose qroups and effects on the red blood picture were present 
in the two hiqhest dose qroups. The main effect was a marked 
increase in tumour incidence. A dose related induction of 
haemanqio-endotheliomas in the heart and adenocarcinomas in the 
small intestine was found in all groups. In the mid and 
high-dose qroups an increase in papillomas and squamous cell 
carcinomas of the forestomach was also observed. Due to early 
mortality in the hiah-dose group, the tumour incidence was 
hiqhest in the mid-dose qroup for liver carcinomas and 
haemanqiomas of the spleen. Liver carcinomas were also found 
in the 750 mg/kg group (7). 
Unlike the experiment by the manufacturer, no increase in the 
incidence of lymphosarcomas was observed; the dose levels in 
the two mouse studies were comparable. The dosages per kg 
b.w., calculated from the food consumption data were, however, 
higher in the Ito study. 
In a chronic studv in the rat, in which dose levels of 0, 75, 
300 and 1200 mg/kg feed were used, no effect on survival was 
observed. Some growth inhibition and effects on biochemical 
variables in the highest dose group of 1200 mg/kg feed were 
observed. The main effect was an increase in kidney tumours, 
especially in the males of the highest dose group. There was 
also an increase in the occurrence of megalocvtic renal cells 
in males and females in the highest dose group. In the liver 
of the females of this group the incidence of neoplastic 
nodules was increased. Females of all groups showed a 
guestionable increase in mammary fibroadenomas. Non-neoplastic 
lesions like ulcerations, hyperkeratosis and acanthosis were 
found in the stomach at the highest dose level (8). In a 
2-vear satellite studv with a dose level comparable with the 
lowest dose group in the chronic rat study no effects were 
observed (9). This study was carried out because it appeared 
that especially at the lowest dose levels there was a decrease 
of the active substance in the feed when it was stored for some 
time at room temperature. Because this loss was much smaller 
for the high dose groups and because these groups showed an 
increased incidence of tumours, the effect is less relevant for 
the evaluation of the toxicity of captafol. 
1.2.2 Mutagenicity 
Manv mutagenicitv studies have been carried out. In vitro 
tests showed that captafol is capable of inducing 
gene-mutations and chromosomal aberrations. In the presence of 
metabolic activation (proteins, mammalian blood, cysteine and 
glutathione) the mutagenic activity is reduced or eliminated in 
most cases. Captafol is probably detoxified in vitro by 
biological thiols and this reaction is also likely to occur in 
vivo. 
In vivo, captafol was negative in a mouse spot-test. An in 
vivo assay for chromosomal aberrations in bone-marrow in the 
rat and a micronucleus test in mice were also negative. An 
increased rate of dominant lethal mutations was observed in two 
of three studies (10). 
1.2.3 Human_daţa 
An epidemiological study carried out by one of the 
manufacturers on 1535 employees involved in the production of 
captafol showed no significant increase of cancer mortalities 
(11). However, it is known that captafol has strong sensitizing 
properties and exposure mav lead to sensitization in operators 
and also in people handling recentlv treated crops and those on 
which dried residues remain. 
1.2.4 Meçhanism_gf_îQxic_acţign 
Metabolism studies in rats, dogs and monkeys showed that the 
primary metabolic step is a cleavage into tetrahydrophthalimide 
(THPI) and tetrachloroethvlthiol (TES) moitiés (12). In recent 
studies special attention was paid to the metabolism of the TES 
group. In the urine the major metabolite was 
2-chloro-2-methylthioethylene sulphonic acid. To explain the 
formation of this metabolite the authors assumed that a cyclic 
sulphonium ion must be formed as a transient intermediate in 
the degradation of TES. This intermediate is a potential 
alkylating agent. The authors also suggested that sulphite 
plays a critical role in the detoxification of TES (12). 
1.3 AGRONOMIC USAGE AND RESIDUES 
Approximately 3500 metric tonnes active substance of captafol 
have been used annually in the Community, with the main use 
being to control Septgria. diseases (§. ngdoiym and §. tritici) 
on wheat (86%). Alternative fungicides, such as 
chlorothalonil, prochloraz and propiconazole are available, but 
their effectiveness needs to be established. This use of 
captafol generally leads to negligible residues occurring in 
the grain although they do arise in the straw in the range of 1 
to 10 ppm. Evidence has been received that residues of 
captafol occasionally occur on fruit and vegetables such as 
pome fruits, grapes, lettuce, endive and potatoes. No residues 
have been found in total diet studies carried out in two 
countries (12a). 
1.4 CONCLUSIONS 
Because captafol caused various types of tumours in both rats 
and mice it has to be considered as a carcinogen in animals 
with initiating properties. Although no carcinogenicity was 
observed in an epidemiological study, potential carcinogenic 
effects on humans at low exposure levels cannot be excluded and 
consequently no ADI could be estimated. Therefore, the MRL for 
captafol should not exceed the limit of determination (at or 
about 0.05 mg/kg). 
In view of the toxicological considerations of captafol 
mentioned above, the Committee concluded that since the 
potential hazards to human health associated with the use of 
captafol as a fungicide cannot be eliminated fully by selective 
reduction of exposure, the prohibition of the use of captafol 
should be envisaged. 
For these reasons, in general, captafol should not be 
used. However for cereals, in which residues are known not 
to occur and where sufficient protective measures can be 
taken to avoid operator exposure, a temporary derogation 
could be envisaged until adequate alternatives are 
available. Likewise, a similar type of temporary derogation 
can also be envisaged for the use of captafol on a certain 
limited number of non-edible crops (i.e. certain flower 
bulbs) for which special protective measures can be taken. 
2. CAPTAN 
2.1 INTRODUCTION 
The toxicity of the fungicide captan has been evaluated by 
the Joint FAO/WHO Meetings on Pesticide Residues (JMPR) in 
1965, 1969, 1973, 1977, 1978, 1982 and 1984 (2). In 1982, 
it became apparent that most of the studies on which the 
acceptable daily intake (ADI) was based had been carried 
out by Industrial Bio-Test Laboratories. Therefore, the 
1982 JMPR replaced the ADI (0.1 mg/kg b.w. established in 
1973) by a temporary ADI of 0.01 mg/kg b.w. and required 
additonal studies. These studies were evaluated by the 
1984 JMPR and the ADI was re-estimated at the original 
value of 0.1 mg/kg b.w. 
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2.2 TOXICOLOGICA!. ASPECTS 
2.2.1 Chronie_ţgxicity_and_çarcinggeniçity 
Three carcinogenicity studies have been carried out in both 
mice and rats. In the 80 week National Cancer Institute (NCI) 
feeding study in mice with dose levels corresponding to 0, 1143 
and 2285 mg/kg b.w., the combined incidence of adenomatous 
polyp and polypoid carcinoma in the duodenum showed a 
significant dose related trend. In addition, growth was 
inhibited at both dose levels (13). In the second study in 
mice with dose levels corresponding to 0, 857, 1429 and 2285 
mg/kg b.w., the incidence of benign and malignant duodenal 
tumours was increased in all dose groups. A higher mortality 
was found in the highest dose group, and growth was reduced in 
a dose related manner in all treatment groups (14). The third 
study in mice was carried out with lower dose levels, 
corresponding to 0, 14, 57, 114 and 857 mg/kg b.w. At the 
highest dose level an increased incidence of non-neoplastic and 
neoplastic lesions in the small intestine was found, especially 
in the duodenum. Mice from this group also showed reduced 
growth. In the case of the 114 mg/kg b.w. treatment no effects 
were found (15, 16). 
In the first rat study (dose levels 0, 25, 100 and 250 mg/kg 
b.w.), a significant trend for kidney adenomas was found. 
However, the incidences were not significantly increased. 
Growth was inhibited at 100 and 250 mg/kg, whereas at 250 mg/kg 
relative liver and kidney weights were increased, and 
microscopically a higher incidence of hepatocellular 
hypertrophy was observed. With 25 mg/kg b.w. no effects were 
found (17). In the second study, with dose levels 
corresponding to 0. 126 and 303 mg/kg b.w. captan did not show 
carcinogenic effects. 
Growth retardation was observed in both treatment groups (13). 
In the third studv, with dose levels of 0, 6.25, 25 and 100 
mg/kg b.w. no carcinogenic action of captan was observed. At 
the highest dose level, reduced growth and food consumption and 
an increased relative weigth was found (18). 
2.2.2 ReQrodycţion_and_ţeraţogeDiciţy 
In earlier studies evaluated bv the JMPR, teratogenic effects 
of captan were reported in hamsters, rats and rabbits. No 
teratogenic effects were seen in mice and monkeys, or in later 
hamster and rabbit studies (19, 20). In a recent 3-generation 
reproduction study in rats with dose levels of 0, 25, 100, 250 
and 500 mg/kg b.w., growth depression and reduced food 
consumption were observed at all dose levels. Effects on 
offspring were found at various dose levels, the most sensitive 
effect being a reduced litter size and pup weight even at 25 
mg/kg b.w. No teratogenic effects were seen (21). Since there 
was no no-effect level, a new one generation reproduction studv 
was carried out with lower dose levels (0, 6, 12.5 and 25 mg/kg 
b.w.). A slight reduction in pup and litter weight was 
observed at 25 mg/kg b.w. In this studv 12.5 mg/kg b.w. can be 
considered as a no-effect level (22). 
2.2.3 Mutagenicity 
Captan is positive in in vitro assavs. In the presence of 
metabolic activation (proteins, mammalian blood, cysteine and 
glutathione) the mutagenic activity is reduced or eliminated in 
most cases. Apparently, captan is detoxified in vitro probably 
bv biological thiols scavenging the reactive intermediates. 
Detoxification is also likely to occur in vivo. Captan was 
predominantly negative in in vivo assays detecting chromosomal 
aberrations and gene-mutations: mouse spot-test, heritable 
translocation test, host-mediated assays, dominant lethal tests 
and micronucleus tests. In some cases the weakly positive 
results were not confirmed in repeated experiments (23). 
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2.2.4 Hyman_daţa 
An epidemiological study was carried out on 134 workers at a 
captan producing plant. Onlv two deaths of the 134 workers 
were caused by tumour conditions (pancreas, thymus); no cancer 
of the duodenum was found (24). 
2.2.5 Metabolism. 
From earlier metabolism studies in rats, it appeared that 
captan was split into tetrahydrophthalimide and in 
trichloromethylthio (TMS) moiety: the latter would appear to be 
the more important in relation to mutagenicity and 
carcinogenicity. Captan is also hydrolysed into these two 
parts in aqueous solution; at pH 8 the reaction rate is much 
higher than at pH 6 or 7. When thiols, such as S-containing 
amino acids, are present TMS reacts with the thiol and 
ultimately thiophosgene is formed. This is further metabolized 
to CO2, thiazolidine-2-thione-carbo-xylic acid (TTCA) and 
thiobis (methanesulphonic acid) and its disulphide monoxide 
derivative. Three metabolites are found after oral dosing, 
while after intraperitoneal administration the latter two 
dithiobis metabolites are not formed. No unchanged captan is 
found in the urine, while in the faeces a relatively high 
percentage of unchanged captan is found after administration of 
a high oral dose level (25). 
In a comparative study with rats and mice a number of 
differences were observed. The elimination rate of 14C-TMS 
captan in the mouse was greater than in the rat. The rat has a 
lower gastrointestinal pH and showed a longer gastric retention 
time. An important difference was found in the percentage of 
radioactivity found in the duodenum. At the high dose of 250 
mg/kg b.w., this was 6.8% and 0.6% for mice and rats 
respectively. 
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From a separate studv, it was concluded that captan remains 
stable under the acidic conditions of the stomach, but then 
degrades or metabolizes readilv at the higher pHs of the 
duodenum. At the low dose of 5 mg/kg b.w., duodenal 
radioactivity was low for both rats and mice (1.7 and 1.1% 
resp.) (26). 
2.2.6 Mechanism_Qf_toxiç_action 
To explain the various findings the following mechanisms of 
action have been postulated (12). Captan in agueous solution 
is readilv split into tetrahydrophthalimide (THPI) and the 
trichloromethvlthio moiety (SCCI3) in the form of a reactive 
compound; this may be the basis for the mutagenic effects found 
in vitro. When S-containing amino acids are present a reaction 
with this group takes place and the product is further' 
metabolized into "harmless" compounds. This may explain the 
protective effect of cysteine and glutathione against the 
mutagenic effects in vitro, and probably also the absence of 
mutageniticy in in vivo tests and the absence of 
carcinogenicity in the rat. 
However, there may be only a guantitative difference between 
mouse and rat. The dose levels in mice at which duodenal 
tumours were found are much higher than the highest levels 
tested in the rat, when expressed in mg/kg b.w. From 
metabolism data, it is known that the percentage of 
radioactivity in the duodenum is higher for mice than for 
rats. It also appears that with higher dose levels more of the 
unchanged captan is passed through the intestines. When a 
large amount of captan passes from the stomach (low pH) into 
the duodenum (high pH) the molecule is hydrolized rapidly. In 
this case, it can be assumed that not enough thiols are present 
to bind the reactive group, which may react with the DNA of the 
epithelial cells of the duodenum. 
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Differences between captan and captafol 
For both compounds, the hydrolysis of the molecule into a IHK1 
and a TMS or TES moiety is probably responsible for the IN vitro mutagenic action. SH-containing amino acids protect 
against mutagenicity by reacting with the TMS or TES-group. 
With captafol, however, although the TES-group is bound, 
metabolites may occur containing a cyclic sulphonium ion which 
is probably alkylating (12). This might explain why with 
captafol, kidney tumours are found in the rat and various 
tumours in the mouse, which are not observed with captan. 
2.3 AGRONOMIC USAGE AND RESIDUES 
Approximately 2700 metric tonnes active substance of captan 
have been used annually in the Community, with the main use 
being on pome fruit (70%) to control scab (Venturia inaequalis) 
and such diseases as Gloesporium, Nectaria and Botrytis. 
Another important use is on grapes (20%) to control mildew and 
grey mould Botrytis cinerea. The residue data available to the 
Committee was fully consistent with the usage pattern referred 
to above, residues occurring frequently on pome fruit, grapes 
and soft fruit. Captan was not found in the UK total diet 
studies but it regularly occurs, particularly in the fruit 
group of the total diet surveys carried out in the USA (12a). 
2.4 CONCLUSIONS 
The Committee concluded that captan is a carcinogen for the 
mouse, causing duodenal tumours at the highest dose levels. It 
is not carcinogenic in the rat. The postulated mechanism of 
toxic action would indicate that captan has a threshold level 
for the carcinogenicity in mice of captan. Experimentally, the 
level of this threshold cannot be determined precisely. 
Therefore, a larger safety factor for the caclulation of the 
ADI is proposed. 
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Based on the no-effect level in the reproduction experiment of 
12.5 mg/kg b.w., with a safety factor of 1000, the AU1 is 
estimated at 0.01 mg/kg b.w. 
In view of the lower ADI now established, the Committee held 
the view that the current Community MRL for captan in and on 
fruit and vegetables should be replaced by MRLs (probably at a 
lower level) for individual crops. However, in order to enable 
that to be done, relevant usage and residue data need to be 
studied in detail. 
3. F0LPET 
3.1 INTRODUCTION 
The toxicity of the fungicide folpet has been evaluated by the 
Joint FA0/WH0 Meetings on Pesticide Residues (JMPR) in 1969, 
1973, 1974, 1982 and 1984 (2). In 1982, it became apparent 
that most of the studies on which the acceptable daily intake 
(ADI) was based had been carried out by Industrial Bio-Test 
Laboratories. Therefore, the 1982 JMPR replaced the existing 
ADI of 0.1 mg/kg b.w. (established in 1973) by a temporary ALU 
of 0.01 mg/kg b.w. and required additional studies. In 1984, 
in view of the absence of most of the required data and because 
of concern over possible teratogenicity in the rabbit, the ADI 
was withdrawn. In 1986 the required data were available and 
the JMPR reinstated the temporary ADI of 0.01 mg/kg b.w. (2). 
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3.2 TOXICOLOGICAL ASPECTS 
3.2.1 Subchronic toxicity 
Three studies have been carried out in the doq. In a α-week 
oral studv with dosaaes from 20 mq/kg b.w., many effects were 
reported including changes in clinico-chemical parameters and 
in organ weights at 180 mg/kg and greater. Clinical signs, a 
reduced food intake and growth were observed in all folpet dose 
groups ('27). Dogs receiving dosages of 790. 1800 and 4000 
mg/kg b.w. for 90 days showed many toxic effects including 
clinical sians, reduced growth and food intake, increased 
mortality, haematological changes and chanaes in 
clinico-chemical parameters and also changes in organ weights 
often in a dose-related manner in all dosage groups. 
Histopathological changes were reported in gonads, thvroid. 
lymphatic and haematopoietic svstems and striated muscles 
(28). Dogs, which were administered oral dosages of 0. 10, foO 
and 120 ma/kg b.w. for 1 year, showed a depressed food 
consumption and growth in the mid and high-dose groups. 
Clinical chemistry revealed decreased cholesterol, total 
protein, albumin and globulin values in the mid and high-dose 
groups. At 10 mg/kg b.w. no effects were found (29). 
Two semichronic studies were carried out in the rat. In both 
studies irritation and other effects in the stomach were 
predominant. In the first semichronic studv in the rat, body 
weight was decreased and changes in some organ weiahts were 
reported at the highest dosage level corresponding to 500 ma/kg 
b.w. Clinical chemistrv revealed decreased protein values, and 
irritation and histomorphologic alterations in the stomach were 
seen in the 150 and 500 mg/kg groups. At 50 mg/kg b.w. no 
effects were found (30, 31). In the other 3-months rat study 
growth was reduced at dose levels corresponding to 200 mg/kg 
b.w. and higher. 
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In addition, increased red cell heamatological parameters (at 
400 mg/kg) and a decreased blood protein level (at 200 mg/kg 
and above) were observed. Another important effect observed 
was irritation of the mucosal squamous epithelium of the 
oesophagus and stomach in all dosage groups. In the kidneys of 
the 200 and 400 mg/kq groups an increase in the number of foci 
was reported. A no-effect level could not be established (32). 
3.2.2 Ghrgniç_tgxicity_and_çarçinggeniçity 
Two long term studies in mice and two in rats were carried 
out. In both mouse studies an increase in the number of 
duodenal tumours was observed. In the first study mice 
receiving dosages corresponding to 0, 143, 714 and 1714 mg/kg 
b.w. revealed an increased incidence of duodenal adenomas and 
adenocarcinomas in the high-dose and in the mid and high-dose 
groups respectively. High-dose males also showed an increased 
incidence of jejunal adenocarcinomas. The incidence of mucosal 
hvperplasia in the duodenum was increased in all folpet dosage 
qroups. Mucosal hyperplasia of the jejunum and ileum occurred 
more frequently in the high-dose group. A variety of other 
effects including affected growth, haematological effects, 
squamous papillomas in the stomach, nodular hyperplasia in the 
liver, effects on the haematopoietic system and cutaneous 
proliferative changes were reported. A no-effect level could 
not be established (2, 33, 34). 
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In a second studv mice received dosages corresponding to 0, 
143, 714 and 1430 mg/kg b.w. for the first 21 weeks and 0, 142, 
500 and 1000 mg/kg b.w. for the remaining 83 weeks. The 
incidence of carcinoma of the duodenum and of papilloma and 
squamous cell carcinoma of the stomach was increased in all 
folpet treated groups. The increased incidence of tumours of 
the stomach was possibly due to mechanical obstruction caused 
bv the duodenum tumours. Other effects consisted of reduced 
life expectancy and growth, clinical signs of toxicity 
associated with the integumentary svstem and several affected 
relative organ weights. Macroscopy revealed lesions of the 
skin, duodenum, jejunum and stomach. Histopathology revealed 
also non-neoplastic changes including hyperkeratosis of the 
skin, oesophagus and non-glandular mucosa of the stomach and 
mucosal hyperplasia in the duodenum and jejunum. A no-effect 
level could not be established (35, 36). 
In the rat studies effects on the stomach were also observed. 
In the first rat studv (dose levels corresponding to 0, 10, 40 
and 160 mg/kg b.w.) no carcinogenic action of folpet was 
observed. The high dose group demonstrated a reduced growth 
and an increased incidence of stomach lesions. With 40 mg/kg 
b.w. no effects were found (37, 38). In the second study with 
dose levels corresponding to 0, 25, 50 and 100 mg/kg b.w. a 
reduced growth was seen in all treatment groups. Amongst organ 
weights, heart, brain and testes were increased at 100 mg/kg 
and testes weight was also increased at 50 mg/kg. 
Histopathologv revealed lesions of the oesophagus and stomach 
and foci or areas of cellular alterations in the liver were 
reported in the mid and high-dose groups. A dose of 25 mg/kg 
b.w. was a marginal no-effect level (39). 
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3.2.3 ReQrgdycţign_aQd_ţeraţogenicity_ 
In earlier studies evaluated by the JMPR (2), teratogenic 
effects of folpet were reported in chicken eggs and hamsters 
whilst no such effects were reported in rabbits. 
In a recent 2-generation reproduction study in rats with dose 
levels corresponding to 0, 10, 40 and 180 mg/kg b.w., growth 
depression and reduced food consumption was reported in the 
high-dose adults of the F0 and Fib generation and in all 
high-dose litters. No effects were noticed at 40 mg/kg b.w. 
(40). 
No teratogenic effects were noted in an oral studv in rats 
receiving dosages varving from 10 to 360 mg/kg b.w. Clinical 
signs of toxicity and reduced weight gain occurred in dams 
receiving 360 mg/kg (41, 42). In a second study in rats 
receiving 0, 150, 550 and 2000 mg/kg b.w. clinical symptoms and 
maternal mortality occurred in the high-dose group. A 
reduction in maternal weight gain, foetal weights and foetal 
crown-rump length was reported at 550 and 2000 mg/kg. Skeletal 
examination revealed significant evidence of delayed 
ossification of the cranial bones, sternabrae and pubes. 
Angulated ribs were observed in all folpet treated groups. The 
foetal no-effect level is below 150 mg/kg b.w. (43, 44). 
Rabbits intubated with folpet increased maternal mortality at 
the highest dose of 60 mg/kg b.w. Maternal body weight gain 
and food consumption were reduced at 20 mg/kg and above as were 
mean foetal body weights. A significant increase in the 
incidence of a so-called "hydrocephaly" (or severe dilatation 
of the lateral ventricles) was reported at 60 mg/kg. No 
effects were noted at 10 mg/kg b.w. (2, 45). In an additional 
study rabbits were given an oral dose of 60 mg/kg b.w./day 
during end of four consecutive three day periods during 
gestation, in order to demonstrate whether the association of 
"hvdrocephalus" and maternal toxicity was specific to a uniaue 
developmental period. 
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Maternal toxicity, expressed as death, abortion, decreased food 
consumption and body weights were reported. Internal 
"hydrocephalus" occurred in two foetuses. No connection was 
made between the presence of "hydrocephalus" and the 
experimental design and no arguments were advanced which could 
support the authors conclusion that the occurrence of this 
malformation was not induced by the substance. Therefore, it 
must be concluded that folpet showed teratogenic effects in 
this study (46). 
Pregnant rabbits receiving 40 and 160 mg/kg b.w. showed a 
reduced body weight gain. At 160 mg/kg post-implantation loss 
was increased and gravid uterine weight and mean foetal weight 
were reduced. Additionally, the number of "small" foetuses was 
increased at 160 mg/kg. Skeletal examination revealed 
developmental retardation (reduced ossification) and an 
increased number of foetuses with a 13th (lumbar) pair of ribs 
or 13 thoracic vertebrae and 13 thoracic ribs at 160 and 40 
mg/kg. No effects were observed at 10 mg/kg (47, 48). 
From the teratogenicity studies it is concluded that folpet has 
potential teratogenic properties in rabbits at a dose level of 
20 mg/kg b.w. 
3.2.4 Myţageniţicy 
Folpet is positive in in vitro assays using bacteria, yeast and 
cultured mammalian cells detecting gene mutations, chromosome 
aberrations and DNA damage. In the presence of metabolic 
activation, blood, cysteine or glutathione, the mutagenic 
activity is often reduced or eliminated. Apparently, folpet is 
detoxified ±D vitro probably by biological thiols scavenging 
the reactive intermediates. 
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Folpet was negative in several in vivo assays detecting 
chromosomal aberrations or gene-mutations: a mouse spot-test 
and tests for micronuclei and chromosome aberrations in bone 
marrow. Gene-mutation tests with Drosophila melanogaster were 
predominantly negative. Out of five dominant lethal tests, two 
(by the same author) were positive and three were negative (49). 
3.2.5 Mechanişm_gf_tgxiç_açtign 
l^C-carbonyl labelled folpet is rapidly absorbed, metabolised 
and excreted in rats. Approximately 95% of the 14C-activity is 
excreted in the urine. Folpet is easily split into phthalimide 
and a trichloromethylthio moiety. Phthalimide is mainly 
metabolised to phthalimic acid and phthalic acid (50). In 
earlier studies a wide range of degradation products of the 
trichloromethvl moietv. such as carbonyl sulfide, thiophosgene 
and sulphur in several oxidation rates, were reported (2). 
Based on the chemical structure and the similarity of the 
toxicity data, the same mechanism of action is proposed for 
folpet as for captan. Both compounds contain the 
trichloromethylthio moiety (SCCI3) which is formed after 
hvdrolvsis and is bound to glutathione. Glutathione also 
showed a clear protective effect against mutagenicity of folpet 
i.G vitro. In viyg this mechanism is also likely to occur. 
This mav explain the low toxicity of folpet. 
The substance is not carcinogenic in the rat, but induces 
tumours in the duodenum, jejunum and stomach of the mouse. 
Dose levels expressed on a mg/kg b.w. basis were much higher in 
mice than in rats. Moreover, it can be assumed that as for 
captan, the percentage of the unchanged active substance 
present in the duodenum is higher in mice at the same dose 
level than in rats. 
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3.3 AGRONOMIC USAGE AND RESIDUES 
Approximately 4,400 metric tonnes active substance of folpet 
have been used annuallv in the Community, with the main use 
being on qrapes (90%) to control downy mildew (Plaşmopara 
viticola) and secondarliν to control Botrytis cinerea). 
Folpet residues have not been observed in any of the United 
Kingdom total diet studies. Occasionally, residues of folpet 
have been found in strawberries, grapes and pears but in no 
case did the levels exceed one-half of the relevant maximum 
residue level (MRU. In the Netherlands, a few samples of 
blackberries and gooseberries contained folpet just above the 
MRL (12a). 
3.4 CONCLUSIONS 
Folpet is carcinogenic for the mouse, causing duodenal tumours 
at the highest dose levels. It is not carcinogenic in the 
rat. The postulated mechanism of toxic action would indicate 
that there is a threshold level for the carcinogenicity of 
folpet in mice but this threshold level cannot be determined 
precisely experimentally. Because of these uncertainties a 
larger safety factor for the calculation of the ADI is 
proposed. Based on the no-effect level in the dog studies of 
10 mg/kg b.w., with a safety factor of 1000, the ADI is 
estimated at 0.01 mg/kg b.w. 
In view of the ADI now established, the Committee held the view 
that the present Community MRLs for folpet on fruit and 
vegetables are not acceptable under current conditions and 
should be reviewed. In order to enable that to be done, 
relevant usage and residue data need to be studied in detail. 
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GENERAL CONCLUSIONS FOR CAPTAN AND FOLPET 
The phthalimide group of fungicides should be regarded as two 
sub-groups, captafol on the one hand and captan and folpet on 
the other. 
For captan and folpet, a carcinogenic effect is found in mice 
but in this case the proposed mechanism of action (see pages 13 
and 14) indicates a threshold level for the effect. Therefore, 
ADIs could be estimated for both captan and folpet using a 
higher than usual safety factor. For each compound the ADI is 
0.01 mg/kg b.w. However, because of the similarity of 
mechanism of their toxic action, it is proposed that the total 
intake of captan and folpet together should not exceed 0.01 
mg/kg b.w. 
It will be necessary to examine closelv the current usage 
patterns and residue level of captan and folpet and their 
relevant maximum residue levels to ensure that intakes remain 
below the ADI. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE USE OF LINDANE AS AN INSECTICIDE AND ITS RESIDUES IN FOODSTUFHS 
(Opinion expressed on 17 Februarv 1988) 
BACKGROUNQ_AND_IERMŞ_QF_REFERENQE 
The use of lindane is authorized in certain Member States as an 
insecticide for use on a wide ranae of fruit and vegetable crops and for 
the control of ectoparasites on some animals. Most of the available 
toxicolooical data are old and based on tests not carried out to modern 
protocols. This is particularly the case for the data used by the Joint 
FAO/WHO Meeting on Pesticide residues ÍJMPR) in 1977 (1) to establish 
the current acceptable dailv intake (ADD (0.01 mg/kg b.w.). However, 
since then the results of new toxicological studies have become 
available. 
The use pattern for lindane has changed in recent years and its usage is 
now low. havina been laraelv superseded by newer insecticides. 
Nevertheless, the Commission considers it prudent in the circumstances 
to reauest the Scientific Committee for Pesticides to examine the 
toxicoloav of lindane and its environmental impact and. on the basis ot 
the former, to estimate, if possible, an acceptable dailv intake and 
accordinolv to consider the appropriateness or otherwise of the existing 
Communitv maximum residue levels. 
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The maximum levels provided for bv Directives 76/895/EEC, 86/.Jfo2/fc.b.L\ 
86/363/EEC (2) at the time of writing were: 
Maximum levels in mg/kg (ppm) 
2.0 
0.1 
1.5 
0.1 
2.0 
1.0 
leaf vegetables 
carrots 
other fruit & veaetables 
cereals (applicable 1st Januarv 1990) 
sheepmeat* ) applicable 
other meat products* ) 30 June 1988 
0.008: milk** ) 
DISCUSSION 
1. TOXICOLOGICA!. ASPECTS 
1.1 Açute_toxicity 
Lindane shows a moderate acute oral toxicitv with a LD50 for rats ot 88 -
300 mg/kg bodv weight with the main effect being on the central nervous 
svstem (3, 4. 5, 6) 
1.2 Irritation 
Lindane is an irritating but a non-sensitizing agent. Ihe irritation 
potencv depends on the tvpe of formulation and the mode of application. 
However, no maior problems need occur when good application practices are 
followed and formulations containing fine dust are avoided, particularly 
in closed spaces (3). 
* in mq/kg (ppm) of fat contained in meat. 
** in mg/kg (ppm) for raw and whole cows' milk assuming a tat content or 
4%. For other milk and milk products covered bv the Directive the 
following applv: 
- products with a fat content of less than 2% by weight, the maximum 
level is taken as half that set for raw milk and whole cream milk: 
- products with a fat content of 2% or more by weight, the maximum 
level is expressed in mo/kg of fat. In such cases, the maximum 
level is 25 times that set for raw milk and whole cream milk. 
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1.3 Short term toxicity 
Two recent semichronic toxicity studies in rats are available, the 
results of which are not in full aqreement (7, 8). In both studies 
effects on livers and kidnevs were observed. Based on the most sensitive 
parameter, the liver enzvme inductive potency, 2 mg/kg feed was 
considered as a no observed effect level. In a semichronic inhalation 
studv in rats, 0.1 mq/m^ was established as a no observed effect level(9). 
1.4 Carcinogenicity and mutagenicity studies 
Several limited chronic toxicity studies were available (1U, 11, 12) the 
results of which were in aqreement with the profile of toxicity arising 
from the semichronic studies mentioned above (7, 8, 9). In the 
carcinogenicity studies in mice, liver tumours were found only at hiqh 
dose levels ( 300 mq/kq feed) (10, 11). This effect was not apparent in 
the available studies in rats (10. 11). Additional short-term studies in 
mice did not indicate qenotoxicity (14, 15). Further support for the 
absence of genotoxicity is provided by the data on mutagenicity: lindane 
was examined in a variety of test-systems usinq different endpoints, 
plants, bacteria, yeast, Drosophila, mammalian and human cells in vitro, 
as well as whole mammals. It did not induce mutations in any of the 
systems examined (17. 18, 20, 21, 23. 24, 25, 2b, 27, 28, 29, 30), 
whereas some cytogenetic damage was observed in mammalian and human cells 
in vitro (11, 16, 22). 
The compound is a mitotic poison in plant-svsterns, thereby inducing 
C-mitosis, polyploidy and chromosome aberrations (11). The increase in 
liver tumours observed in the mouse studies is not considered sufficient 
evidence for carcinogenicity of lindane. The increase of adenomas and 
carcinomas in the mouse liver is probably associated with the enzvme 
induction effects of lindane in the liver; this may be due to a promotor 
effect. 
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1.5 Acceptable daily intake - Human exposure to Lindane 
Since the existing acceptable daily intake (ADD of 0.01mg/kq b.w. (1) is 
not based on adequate studies, the Committee considered that a 
réévaluation of the ADI is necessary. In general, estimation of an ADI 
reauires an adeauate chronic toxicity study in rats. Although the 
Committee was aware that such a study is in progress, it was of the 
opinion that in the case of lindane available experimental data on the 
chronic toxicity and carcinogenicity (10, 11, 12, 14, 15)in combination 
with the results of the two more recent adequate semi-chronic toxicity 
studies (7. 8) are considered to provide a sufficient basis for 
establishment of an ADI using a safety factor of 100. From the 
semi-chronic toxicity studies in rats (7, 8) a no-effect level of 2 mg/kg 
feed (0.1 ma/kg b.w.) can be concluded . This results in an ADI of 0.UU1 
mg/kg b.w. (60 ug/dav/person). 
The main source of human exposure is from the diet, particularly from 
foodstuffs of animal origin. This includes residues from direct 
aaricultural use and also extraneous residues in the food from 
environmental sources. In the Netherlands. the daily dietary intake 
during the period 1976-1978 ranged up to 16 ug/person with a mean value 
of 2 ug/person (31. 32). Studies in the United Kingdom showed levels of 
lindane of 4. 2.5 and 1.5 ug/kg in the diet in 1966-67, 1975-77 and 1981 
respectively (33), corresponding to 4.5 - 12 ug/pexson. Both data 
sources indicate low dietary exposure to lindane when compared to the 
acceptable daily intake of 60 ug/person . 
In addition, the possibilitv exists of localized intake mainly by 
inhalation from other sources, such as wood preservative treatments and 
household insecticide use. For instance, information is available that 
levels of up to 60 ug/m can D e reached in poorly ventilated houses where 
lindane has been used for remedial wood treatment (34· 35). This level 
is verv close to the no effect level of 100 ug/m' found in a semi-chronic 
inhalation study with rats (9). Similar data have been obtained after 
carpet treatments (36). 
Since less volatile alternative compounds are available, the use of 
lindane for remedial wood preservation and household insecticidal 
purposes should be discouraged. 
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2. AGRONOMIC USAGE AND RESIDUES 
Approximately 2 500 metric tonnes active ingredient of lindane are used 
annually in the Community mainly as soil, seed and wood treatments. 
Residues of lindane occur, usually at low levels, in many foodstuffs, 
especially vegetables, cereals and foods of animal oriain. The maximum 
residue levels provided for bv Directives 76/895/EEC, 86/362/EEC and 
86/363/EEC (2) were based on data arising from uses prevalent many years 
ago. In the light of the reduced ADI and especially the changed usage 
patterns. the Committee concluded that the current MRLs should be 
replaced (probablv at lower levels) by MRLs for individual crops. 
However, in order to enable this to be done, relevant current usage and 
residue data would need to be studied in detail. Meanwhile, the current 
MRLs should continue in use. 
3. ECOLOGICAL ASPECTS 
3.1 EnvirQnmenţal_cgntam±DiţiQD 
Lindane is known to be guite toxic to aguatic organisms with, for 
example, an LC5Q - 96 hours - of 2 ug/1 and 152 ug/1 for Salmo trutta and 
Carrasşiuş auraţyş respectively (37, 38, 39, 40). In addition, fish food 
oraanisms. such as small crustaceans are very susceptible (38). 
Therefore, the main concern is to avoid application, handling or disposal 
practices, such as aerial application or improper disposal which could 
aive rise to sprav drift or runoff into water. In this respect, it is 
reassuring that the current uses in the Community are mainly as 
superficial soil treatments against soil borne insects and seed 
treatments against similar insects: there are also localized treatment 
uses, for instance, in forestry and on felled timber. Furthermore, the 
use of lindane on aerial parts of plants has been replaced to a large 
extent bv newer insecticides. 
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Lindane can be found in soil, air and water and on plants, far from areas 
of contamination/application due to its mobilisation from soil and escape 
into the atmosphere. However, contamination of the environment seems to 
be more related to improper disposal of waste arising from the 
manufacture of lindane which contains the other isomers, especially the 
alpha and beta isomers. In addition, disposal of the waste arising trom 
sheep dipping and wood treatment may cause localised contamination of the 
environment bv lindane. 
Lindane is much less persistent in soil when compared to most other 
organochlorine pesticides, having a dissipation time (DT50) in the ranqe 
of 100 - 700 davs (41). Dissipation time is highly dependent on such 
factors as volatilization, soil treatment techniaues, soil types, 
moisture content, temperature and soil crop coverage. However, under 
anaerobic conditions (eg flooded fields) much higher dissipation rates 
have been reported (42. 43, 44). Leaching of lindane in soil does not 
pose a problem and investigations have shown that measurable amounts of 
lindane will very rarely be found below 50 cm following application to 
top-soil layer 0 - 10 cm (45, 46, 47. 48. 49). 
Significant contamination of surface water will not occur following 
judicious use of lindane. However, in this context, it is necessary to 
explain reports of contamination levels of between 20 and 130 ng/1 gamma 
HCH in the rivers Rhine and Meuse (in the Netherlands) for the period 
1974-82. Since the Rhine samples also revealed contamination with other 
isomers of HCH, it is reasonable to surmise that the pollution was of 
industrial rather than of agricultural origin (50). Rain-water has also 
been reported to contain residues of gamma HCH. For instance in 1986. 
the total annual deposit of qamma HCH in The Netherlands was reported to 
be in the range 200-250 ug/m2 (51, 52. 53); the source of this 
contamination remains unknown. 
After consideration of the relevant environmental data on lindane, the 
Committee concluded that, within the Communitv, the potential 
environmental hazards seem to be more related to improper disposal of HCH 
waste than to the current use of lindane in agriculture and in some other 
fields. 
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3.2 BÍQraççymulatign_z_Fggd._çhain_.effecţş 
In contrast with several other orqanochlorine compounds, such as Dui, 
dieldrin, heptachlor and HCB. lindane can only be considered as 
moderatelv bio-accumulative and furthermore no distinct food-chain 
effects on either terrestrial or aquatic orqanisms have been reported to 
arise from current aqriculturai practice, due to the lower rate of 
bio-accumulation and the relatively quick elimination of the compound. 
In products of animal oriqin, lindane is transferred to a lesser extent 
than anv other organochlorine pesticide, with the exception of 
methoxychlox. The transfer coefficient for lindane in cows* milk, 
expressed as a percentage of the daily intake excreted in the milk, 
ranged in various studies between 1.5 and 2.9%. The corresponding 
coefficients for dieldrin and heptachlor epoxide were reported in the 
range 17.1-25.8% and 21.9-32.6% respectively (54, 55, 56). Chickens fed 
for 52 days with 0.3 mg/kg lindane in the feed reached a plateau of 1 
mg/kg in the fat, equivalent to a ratio of 1:3. Corresponding ratios for 
DDT and heptachlor epoxide were reported at 1:10 and 1:13 respectively 
(57). 
4. CONCLUSIONS 
The Committee noted the incidence of liver tumours in mice but found it 
reassuring that this effect was only evident in mice at high dose levels 
and that no genotoxic or mutagenic effects have been reported. Based on 
the no-effect level in the rat studies of 0.1 mg/kg b.w., with a safety 
factor of 100, the ADI is estimated at 0.001 mg/kg b.w. In view of the 
ADI established, and more particularly the changed usage pattern, the 
Committee concluded that the current Community MRLs 'should be reviewed. 
In order to enable this to be done, relevant up-to-date usage and residue 
data need to be studied in detail. 
With respect to the environmental impact of lindane, the Committee 
concluded that there is a potential danger of toxic effects to aquatic 
ecosystems but that this could be sufficiently controlled by adherence 
to practices which avoid sprav drift and runoff into water. The 
Committee was satisfied that lindane, as currently used in aqriculture 
and some other fields, shows no tendency to leach into groundwater or to 
accumulate in terrestrial or aquatic food-chains. 
-35 
REFERENCES 
1. FAO/WHO Evaluations of some pesticide residues in food: 
1966. 1973. 1977 
2. OJ N° L 340, 9.12.1976, p. 36/L 221, 7.8.1986. p. 37/L 221, 7.8.1986, 
p. 43 
3. Blaquière, C. et al. 1972. Lindane - Monograph of an insecticide, 
Freiburq im Breisqau, Verlaq K. Schillinqer, 1972. 
4. Pasquet, J. et al. 1981. Lindafor-flo - Suspension concentrée à /5U 
o/litre de lindane (3201 R.P.). Toxicité aiguë chez le rat par voie 
orale. Departement de Toxicologie Centre Nicolas Grillet - Rhône 
Poulenc. Note C.R. Vitxv/C.N.G. N° 21262 du 22.12.1981. 
Confidential data provided bv Agriben Nederland B.V. 
5. Portig, J. and Vorland. H.W. 1979/85 Neuropharmalkologische und 
neurtoxische Wirkunoen von Hexachlorocvclohexan (HCH). In 
Hexachlorcvclohexan als Schadstoff in Lebensmittel, Materialen aus 
zwei Kolloquien der Senatskommission zur Prüfung von Rückständen in 
Lebensmitteln am 28/29 November 1979 und 6 März 1980. 
6. Haves, W.J. 1982. Pesticides studied in man, Ist. ed., 
Baltimore/London. Williams and Wilkins, pp. 211-228. 
7. Suter P. et al., 1983. Three months toxicity in rats with lindane. 
Report part 1. 2 and 3. Research and Consulting Company Ltd., 
proiect 005220. Celamerck document N° 111 AA-433-07 Report dated 3 
Februarv 1983. Confidential data provided by Celamerck. 
8. Van Velsen, F.L. et al. 1984. Semichronisch oraal 
toxiciteitsonderzoek van gamma-HCH in de rat, Rijksinstituut voor 
Volksgezondheid en Milieuhygiene, Bilthoven, Report N° 618209001, 
dated October 1984. Confidential data. 
36 
9. Leber G. 1983. Inhalations Versuch über 90 Tage mit Lindan, 
Fraunhofer Institut für Toxikologie und Aerosolforschung, Projekt 
Nr. 104264. Report dated 24/4/83. Confidential data provided by 
Celamerck. 
10. Environmental Protection Agency (EPA) 1977. Rebuttable presumption 
against registration and continued registration of pesticide 
products containing lindane. Federal Register, 17/2/77, Part IV. 
11. IARC-1979 Monographs on the evaluation of the carcinogenic risk of 
chemicals to humans. Some Halogenated Hvdrocarbons - Volume 20. 
International Agencv for Research on Cancer, Lyon. October 1979. 
World Health Organisation (WHO) pp. 195-239. 
12. Fitzhugh, O.G. et al. 1950. The chronic toxicities of technical 
benzene hexachloride and its beta and gamma isomers. J. of Pharm. 
Exp. Therapeutics. Vol. 100 (1):59 - 66 
14. Iverson, F. et al. 1984. In vivo and in vitro binding of alpha- and 
gamma- hexachlorcvclohexane to mouse liver macromolecules. 
Toxicoloov Letters; Vol. 20(3): 331-335. 
15. Saoelsdartt, P. et al. 1983. The relevance bf covalent binding to 
mouse liver DNA to the carcinogenic action of 
hexachlorocvclohexane-isomers. Carcinogenesis, Vol. 4(10): 
1267-1273. 
16. Ishidate M., Odashima S.. 1977. Chromosome tests with 134 compounds 
on Chinese hamster cells in vitro - A screening for chemical 
carcinogens. Mut. Res. 48: 337-354. 
17. Tsushimoto G. et al., 1983. Cytotoxic, mutagenic and cell - all 
communication inhibitory properties of DOT, Lindane and Chlordane on 
Chinese hamster cells in vitro. Arch. Environ. Contam. Toxicol. 12: 
721-730. 
-37 
18. Sommer S. et al. 1972. Lindan - Prüfung auf mutagene Wirkung 
Dominanter Letaltest and männlichen Mäusen. Merck-Medizinische 
Forschung/Institut für Toxikologie, report dated 4.8.1972. 
Confidential data provided bv Merck. 
20. Sinha R.R.P. , Sinha S.P., 1983. Induction of dominant lethal 
mutations in Drosophila melanogaster by three pesticides -
gammexane. sevin and folidol. Comp. Physiol. Ecol. 8: 87-89. 
21. Van Dijck P., Van de Voorde H., 1976. Mutagenicity versus 
carcinogenicity of organochlorine insecticides, Med. Fac. Landbouw 
Rijksuniversiteit Gent, 41/2: 1491-1498. 
22. Rohrborn G.. 1975. Scientific statement on mutagenicitv of 
Lindane. Celamerck document n° 111 AA-457-13, report dated 5 
December 1975. Confidential data provided bv CIEL. 
23. Rohrborn G., 1977. Mutagenicitv of Lindane in the 
Salmonella/microsome test: Additional tests with sub-bacteriostatic 
doses, Celamerck document n° 111 AA-457-16, dated 6 January 1977. 
Confidential data provided bv CIEL. 
24. Rohrborn G., 1976. Scientific statement on the mutagenicity of 
Lindane in host-mediated assay according to Legator, Celamerck 
document n° 111 AA-457-15. dated 2.9.1976. Confidential data 
provided bv CIEL. 
25. Rohrborn G., 1976. Cytogenetic analysis of bone marrow of Chinese 
hamster (Cricetulus griseus) after sub-acute treatment with 
Lindane. Celamerck document n° 111 AA-457-08, report dated 29 July 
1976. Confidential data provided bv CIEL. 
26. Rohrborn G., 1977. Dominant lethal test after treatment of male 
rats with Lindane. Celamerck document n" 111 AA-457-04, report 
dated 25 Januarv 1977. Confidential data provided by CIEL. 
38 
27. Oesch F.. 1980. Bacterial mutagenicity tests of lindane with mouse 
liver preparations as metabolizing systems. Celamerck document n" 
111 AA-457-06. dated 20 June 1980. Confidential data provided bv 
Celamerck. 
28. Guenard J. et al., 1984. In vivo sister chromatid exchange assav. 
Celamerck document n° 111 AC-457-020, dated 21 June 1984. 
Confidential data provided bv ÇIEL. 
29. Guenard J. et al., 1984. In vivo sister chromatid exchange assay in 
CF1 mouse bone marrow cells with Lindane (Intraperitoneal 
injection). Celarmerck document n° 111 AC-457-021, dated 19 Julv 
1984. Confidential data provided by CIEL. 
30. Glatt H.R., 1984. Mammalian cell (V 79) mutagenicity test on 
Lindane. Celamerck document n° 111 AC-457-019. dated 28 May 1984. 
Confidential data provided by CIEL. 
31. StaardinkT. and Hakkenbrak P. 1982. Het contaminantenboekje, 1982. 
Hoofdinspectie voor de levensmiddelen en de keuring van waren, 
Ministerie van Volksgezondheid en Milieuhygiene. 
32. Staarink T. and Hakkenbrak P. 1984. Het contaminantenboekje, 1984. 
Hoofdinspectie voor de levensmiddelen en de keuring van waren , 
Ministerie van Weizin Volksgezondheid en Cultuur. 
33. Ministry of Agriculture, Fisheries and Food 1986. Report of the 
Working Party on Pesticide Residues (1982 to 1985). The sixteenth 
report of the Steering Group on Food Surveillance. Her Majesty's 
Stationery Office, London. 
34. Dobbs A.J. and Williams N. 1983. Indoor air pollution from 
pesticides used in wood remedial treatments. Environmental 
Pollution (Series B) 6: 271-2%. 
-39 
35. Reus. H. 1982. Het concentratieverloop van lindaan in een woonhuis 
na toepassing van "Paracide". Unpublished report National Food 
Inspection Service, office Groningen The Netherlands ηβ 82.28. 
36. Scheper, A. and Brunink, Η. 1976. Residuen van 
huishoudbestrijdingsmiddelen. Unpublished report National Food 
Inspection Service, office Groningen, The Netherlands. 
37. Macek. K.J. and McAllister, W.A. 1970. Insecticide susceptibility 
of some common fish family representatives. Trans. Am. Fisheries 
Soc. 99(1): 20-27. 
38. Verschueren, K. 1983. Handboek of environmental data on organic 
chemicals. 2nd ed. p. 720-725. 
39. O'Brien R.D. 1967. Insecticides, Action and Metabolism, Academic 
Press, New York/London. 
40. Tarrwell, CM. 1963. In 'Pesticides - Their use and effects' 
(Swanson, G.A. Ed.). Ν.Y. State Legislative, Albany, New York. 
41. Lichtenstein. E.P. and Schulz, K.R. 1959. Breakdown of lindane in 
soils. J. Econ. Ent. 52(1): 118-124. 
42. Kohnen. R., Haider, K. and Jagnon, G. 1975. Investigations on the 
microbial degradation of lindane in submerged and aerated moist 
soil. Envir. Qual. and Safetv Vol. Ill (Coulston, F. and Korte, F. 
Eds.) p. 222-225. G. Thieme, Stuttgart. 
43. McRae, J.C.. Yamaya. Y. and Yoshida, T. 1984. Persistence of HCH 
isomers in soil suspensions. Soil Biol. Biochem. 16: 285-286. 
44. Rao, P.S.C, and Davidson, J.M. 1982. Retention and transformation 
of selected pesticides and phosphorus in soil-water systems: A 
critical review. EPA 600/3-82-060. Us Dept. 
40-
45. Voerman, S. and Besemer, A.F.H. 1970. Residues of dieldrin lindane, 
DDT and parathion in a light sandy soil after repeated application 
throughout a period of 15 years, J. Agr. Food Chem. 18(4): 717-719. 
46. Voerman, S. and Besemer, A.F.H. 1975. Persistence of dieldrin, 
lindane and DDT in a light sandv soil and their uptake by grass. 
Bull. Env. Contamination and Toxicology 13 (4): 501-505. 
47. Edwards, C.A. 1965. Insecticides residues in soil. Res. Review 13: 
83-132. 
48. Yule, W.N.. Chiba, M. and Morlev, H.V. 1967. Decomposition of 
lindane in soil. J. Agr. Food Chem. 15: 1000-1004. 
49. Lichtenstein. E.P., Fuhremann, T.W. and Schulz, K.R. 1971. 
Persistence and vertical distribution of DDT, lindane and aldrin 
residues 10 and 15 vears after a single soil application. J. Agr. 
Food Chem. 1?: 718-721. 
50. Wegman, R.C.C. 1983. Organische Microverontreinigingen in the 
Rijkswateren (samenvattend rapport over 1982). Unpublished report 
National Institute of Public Health and the Environement, Bilthoven, 
The Netherlands. Report N° 218107003. 
51. RIVM/KNMI. 1988. Data on gamma HCH levels in rain. Private 
communication - report to be published in 1988. 
52. CCRX.1986. Measurements of radioactive and xenobiotic substances in 
the biological environement in the Netherlands 1985. Annual report 
of the coordinating committee for the monitoring of radioactive and 
xenobiotic substances. 
53. Hofstee, A.W.M. 1984. Organische microverontreinigingen in natte 
depositie. Rijksinstituut voor Volksgezondheid en Milieuhygiene 
Report N° 217810007, dated March 1984. Confidential data. 
-41 
54. Hascoet, M. and Kerhoas, L. 1972. Etude expérimentale de ia 
contamination de lait par les insecticides organochlorés présent 
dans la nourriture de l'animal. C.R. Acad. Agrie. 58: 998-1005. 
55. Van den Hoek, J., Salverda, M.H. and Tuinstra, L.G.M.Th. 1975. lhe 
excretion of six orqanochlorine pesticides into the milk of the 
dairv cow after oral administration. Neth. Milk Dairv J. 29: 66-78. 
56. Williams, S. and Mills, P.A. 1964. Residues in milk of cows fed 
rations containinq low concentrations of five chlorinated 
hvdrocarbons. J. Assoc. Offie. Aqr. Chemists 47: 1124-1128. 
57. de Vos, R.H., Bouwman, J. and Enael, A.B. 1972. Residues of 
orqanochlorine pesticides in broilers from feed fortified with known 
levels of the compounds. Pestic. Science 3: 421-432. 
-42 
REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THI RAM 
(Opinion expressed on 25 May 1988) 
BACKGROUND AND TERMS OF REFERENCE 
In the context of its work to review Annex II of Council Directive 
76/895/EEC relating to the fixing of maximum levels for pesticide 
residues in and on fruit and vegetables (1), the Commission invited the 
Scientific Committee for Pesticides to examine the toxIcological data 
on thlram. On the basis of this evaluation, the Commission requested 
the Committee to estimate, If possible, an acceptable daily intake for 
the compound and accordingly to consider the appropriateness or 
otherwise of the existing Community maximum residue levels. 
The levels provided for by Directive 76/895/EEC at the time of writing 
were: 
Maximum levels In ma/ka (ΡΡΙΡΊ 
3.8: strawberries and grapes 
3.0: other fruit and vegetables. 
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DISCUSSION 
1. INTRODUCTION 
In 1985 the existing temporary acceptable dally Intake (ADI) of 
0.005 mg/kg body weight was withdrawn by the Joint FAO/WHO meeting on 
Pesticide Residues (JMPR) because of the lack of adequate toxicologlcal 
data. The reevaluation in 1987 showed that the newly submitted data 
raised additional questions, particularly concerning mutagenicity, 
teratogenicity, reproduction and neurotixlclty. The JMPR was unable, on 
the available data, to estimate an ADI In 1987 (2). 
2. SUMMARY OF TOXIC0L0GI CAL DATA 
2.1 Metabolism 
Thlram is absorbed rapidly In the gastro-intest Inai tract and excreted 
mainly unchanged in the urine and faeces. Formation of 
dimethyldlthiocarbamic acid, CS 2, H2S and dimethylamine have also 
been described. 
2.2 General toxicity 
Thlram has a low acute oral toxicity, with an LD50 for rats of 
1800 - 4000 mg/kg body weight (2, 3). Animal studies have shown it to 
be irritating to the eye (5) but not to the skin (6), whilst moderate 
sensitivity has been shown in guinea pigs (7). For humans, the 
substance must be considered as both irritating and sensitising. 
In a semi-chronic study in rats many toxic effects were found at the 
dose levels of 1.000 and 2.500 mg/kg diet with Increased mortality, 
decreased body weight and food consumption, decrease In lymphocytes and 
increase in neutrophils, increase in both urea and transminase activity 
in blood. The relative weights of spleen, testes and thyroid were 
increased. Hlstopathology revealed both increased haemoslderosis in the 
spleen and tubular degeneration of the testes with the presence of 
atypical spermatids in the epidldymus. Even at the lowest dose level of 
500 mg/kg diet the effects on body weight, food consumption and 
relative spleen, testes and thyroid weights were still evident (3,4). 
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In a second sem i-chronic study In rats, decreased body weight and 
Increased activity of transaminases were found at 600 mg/kg feed. At 
this dose level a slight cholanglolIt Is was observed. In this study no 
effect was found at 300 mg/kg diet (8). 
In a chronic 18-month feeding study in rats, body weight gain and food 
Intake were decreased at all dose levels (corresponding to 5/6, 20/25 
and 50/65 mg/kg body weight per day for males and females 
respectively). One animal at the mid-dose and four at the high dose 
developed hind-limb ataxia. The clinical signs were comparable to those 
described In the semi-chronic studies with the addition of fatty 
infiltration of the pancreas occurring In a dose-related manner. In the 
rats showing ataxia, histology revealed demyelinisation and 
degeneration of the axis cylinders of sciatic nerves (3, 4). 
2.3 Reproduction 
Studies on reproduction are inadequate due to the absence of a two 
generation reproduction study. However, results from preliminary 
studies suggest that thi ram may have an effect on reproduction In males 
and females at high dose levels (4, 10). 
2.4 Teratogenicity and embrvotoxlei tv 
Teratogenicity studles gave contradictory results. Oral administration 
to mice at 10 to 30 mg/kg body weight per day from the 6th to the 15th 
day of gestation resulted in teratogenic and embryotoxic effects (cleft 
palate, micrognathy, kyphoses, wavy and distorted ribs and wavy and 
blockshaped bones of the extremities) at all dose levels with a linear 
dose-effect relationship. Furthermore, 30 mg/kg body weight on day 12 
and 13 of gestation resulted in an increased overall level of 
malformation compared with the same dose level administered from day 6 
to 15 (9). In another study on mice, dose levels of 100 and 300 mg/kg 
body weight administered from day 6 to 14 of gestation showed only 
slight teratogenic and embryotoxic effects. However, the experiment Is 
difficult to interpret in the absence of a clear dose response 
relationship; in addition, 20% maternal mortality occurred at the high 
dose. 
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In a teratogenicity study on rats, maternal toxicity was observed at 
all dose levels (40, 90, 136, 164 mg/kg body weight administered from 
day 6 to 15 of gestation). At the two highest dose levels increased 
resoprtions were observed, and foetal body weight was decreased at all 
dose levels. The increase in total anomalies that occurred may be 
regarded as embryotoxic effects at maternal toxic dose levels. Definite 
teratogenic effects were not observed (3, 10). In a second 
teratogenicity study in rats using dose levels of 0, 12.5, 25, 50 and 
100 mg/kg body weight on day 6 to 15 of gestation, maternal and foetal 
toxicity was observed at dose levels of 25 mg/kg body weight and 
higher. Several embryotoxic effects were found at these dose levels. 
Anomalies affecting the skull were rather high In all experimental 
groups (including the saline control group but not In the methyl 
cellulose control group) without any dose response. The possible effect 
on skull retardation at 12.5 mg/kg body weight is doubtful in view of 
discordant results between the two negative control groups (11). It 
seems questionable whether 12.5 mg/kg body weight can be regarded as 
the embryotoxic no effect level. 
Recently a third teratogenicity study in rats has been received, using 
dose levels of 0, 7.5, 15 or 30 mg/kg b.w. on day 6 to 15 of gestation. 
Maternal and foetal toxicity was observed at 15 and 30 mg/kg (alopecia, 
decreased body weight In the dams; lower foetal weight and retarded 
foetal development). At 7.5 mg/kg a slight growth Inhibition of the 
dams and a lower placental weight were the only effects. This level can 
be considered as a dose without effect (26). Also a recent 
teratogenicity study in rabbits has become available, using dose levels 
of 0, 1, 2.5 or 5 mg/kg b.w. on day 6 to 19 of gestation. A slight 
decrease in maternal body weight gain was observed at 5 mg/kg (27). 
This level can be considered as a dose without embryotoxic or 
teratogenic effect. 
2.5 Mutagen ici tv and carcinogenicity 
Many tests have been carried out to investigate the mutagenic potential 
of thlram with positive and negative finding being reported In several 
In vivo and In vitro test systems. 
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Th I ram was mutagenic in a number of tests with bacteria (12, 13, 14, 
28) and Aspergi I lus nldulans (12, 15). It was positive In one gene 
mutation assay in mammalian cells (16), but negative In the other (17). 
Tests for chromosomal aberrations gave positive results in one at 
cytotoxic dose levels (18) and negative results In another test (23). 
Metabolic activation In in vitro tests generally seemed to weaken the 
mutagenic effect. An anaphase-telophase test In CHO-cells and an 
unscheduled DNA synthesis (UDS) test in rat hepatocytes were negative 
(19, 20). 
In vivo tests also gave contradictory results. Thlram was positive In 
two mlcronucleus tests (16, 19), a sperm abnormality test (12) and a 
test for chromosomal aberrations In mice spermatocytes (29), but 
negative In another mlcronucleus test (24). In many cases the purity of 
the thlram tested is not known (13, 15, 19, 29) or the test was carried 
out with a formulation (14, 16). 
A two-year carcinogenicity study in rats using dose level of 500 and 
1000 mg/kg diet did not show enhanced tumour Incidence (21). In a 
further two-year study with rats of the same strain, 500 mg/kg diet 
again showed a similar result. However, In this study, the addition of 
2.000 mg/kg nitrite clearly induced tumours of the nasal cavity and 
papillomas of the forestomach by the formation of a N-nitroso 
derivative (22). 
3. ENVIRONMENTAL ASPECTS 
Thlram may be degraded in water by light and dlmethylnitrosamine (DMNA) 
can be formed when nitrites are present. Furthermore, DMNA is formed at 
significant levels In Daphnia and fish (Cyprinus carpio) when thlram 
and nitrites are added to the aqueous medium. In a short-term 
laboratory test, increased toxicity to fish (Brachvdanlo rer io) was 
evident when nitrite levels were increased In the presence of 0.1 mg/I 
thlram. In an experimental food chain, Chlorella produced nitrites from 
nitrates and was toxic via Daphnia to fish (Brachvdanlo rer lo) (25). 
Another aspect to be stressed Is the risk for environmental species 
related to the mutagenic potential of thlram Itself. 
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4. CONCLUSIONS 
Th i ram Is embryotoxlc in rats at high dose levels and not embryotoxic 
in rabbits. The dose without effect on the embryos is 7.5 mg/kg in rats 
and 5 mg/ kg In rabbits (highest dose level). Some indications for 
teratogenic effects were observed in mice but not.in rabbits and rats. 
Adequate reproduction studies are lacking. In semi-chronic and chronic 
toxicity feeding studies, effects, especially on body weight, have been 
found at all dose levels. Furthermore, thiram has demonstrated 
mutagenic properties In some tests. There are, however, no Indications 
for a carcinogenic effect of thiram by itself. Due to the lack of a 
no-effect level and the Inadequacy of the toxlcological data package an 
ADI cannot be estimated. Therefore, the Committee was unable further to 
evaluate the safety of the existing Community maximum residue levels 
(MRLs) at the present time. 
Further toxlcological data are required in order to assess adequately 
the safety of thiram. In this context, the following data are 
particularly necessary: a two generation study in rats, an oral sub-
chronic toxicity test in rats showing a no effect level, a dominant 
lethal test and another In vivo mutagenicity test confirming or 
otherwise the positive results reported by Prasad et al in 1987 (29). 
In the light of the above considerations, the Committee considered that 
the current MRLs should be reviewed taking into account current usage 
patterns with a view to establishing MRLs for individual fruit and 
vegetables crops, probably at lower levels that the existing figures. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE USE OF ALACHLOR AS A HERBICIDE 
(Opinion expressed on 25 October 1988) 
BACKGROUND AND TERMS OF REFERENCE 
Alachlor Is the common name for 2-chloro-2', 6'-dlethyl-N-
methoxymethylacetanlI ide (BSI, Ε-ISO, ANSI, WSSA, JMAF). Its 
solubility in water is 242 mg/l at 25"C and its vapour 
pressure is 2.9 mPa at 25'C. It is stable to ultra-violet 
radiation and is hydrolysed under strongly acid or alkaline 
condi t ions. 
Aiachlor is used in certain Member States as a pre-emergence 
herbicide on maize and also, to a limited exent, as a pre-
emergence or post-emergence treatment In soya, sunflower 
potatoes, green beens, brassicas, etc. 
The Commission requested the Scientific Committee for 
Pesticides to examine the toxicology of alachlor in relation 
to its application and to give an opinion on the following 
question: "Is the use, in accordance with good agricultural 
practice, of alachlor prejudicial to human health or the 
environment and, if so, can such dangers be eliminated by 
selective reduction of potential exposure?" 
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DISCUSSION 
1. TOXICOLOGICAL ASPECTS 
1.1 Pharmacokinetics In mammals 
Comprehensive studies of the pharmacokinetic behaviour of 
alachlor revealed that no significant differences In the 
metabolism exist which are dependent-on the route of 
administration or on the doses applied. However, there are 
considerable differences in metabolism, distribution and 
excretion, between rodents and primates. Extensive studies 
were performed In rats and monkeys but those for the mouse 
were limited and inadequate. Some metabolic studies In 
operators were also available (1-16, 22, 23). 
The excretion of alachlor and its metabolites in urine and 
faeces is much slower in rats (biphasic: b- half life of 
approximately 7 days) than in mice (monophasic: half life of 
approximately 24 hours); whilst in monkeys the overall 
elimination ha If-1 i ves in a two-compartment model were 
calculated at 3.5 and 6.5 hours (12, 14-21). 
Mice excrete alachlor metabolites predominantly via the 
faeces; rats 50:50 - urine: faeces; whilst In monkeys 
excretion via urine prevails (12, 14-16, 22, 23). 
It is assumed that a major group of the numerous metabolites 
in the rat urine (14 Identified out of 30, e.g., the 
methyl su I fox ides and methylsulfones) are formed by biliary 
excretion of mercapturic acid pathway metabolites with their 
subsequent enterohepatic circulation and extensive further 
metabolism. A similar complex pattern of urine metabolites 
was observed in mice but with large quantitative differences. 
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In monkeys, only five major urinary metabolites were found and 
identified. In contrast with rats and mice, metabolism in 
monkeys mainly occurs by conjugation with glutathione, 
followed by transformation via the mercapturlc acid pathway, 
leading to a mercapturlc acid and a cysteine conjugate. 
Furthermore, methyl su I fox ide and methyl su I fone metabolites 
were not found in monkeys' urine, indicating that 
enterohepatIc circulation does not make a significant 
contribution to the metabolism of alachlor In monkeys (12, 14-
17, 19, 21, 23-32). 
A suspected key metabolite with respect to the carcinogenicity 
of alachlor is 4-amino-3,5-diethylphenol (ADEP). It was found 
in much larger quantities in the urine of rats than in mice 
and monkeys. In vitro studies with liver and nasal tissue 
preparations showed that 2,6-diethylanlI Ine (DEA) Is a likely 
precursor for ADEP, which is excreted as the sulfate 
conjugate. In rats both tissues contain enzymes of high 
activity necessary to convert secondary amide metabolites of 
alachlor to DEA and to oxidise DEA to ADEP. This phenol 
intermediate may give rise to the formation of a highly 
electrophlIIc benzoiminoquinone, which Is thought to be the 
ultimate carcinogenic alachlor metabolite. Oral 
administration of 1 4C labelled alachlor resulted In high 
levels of radioactivity in rat nasal turbinates but not in 
mice and monkeys. Application of a main rat metabolite, 
alachlor-methylsulfIde, resulted in an even higher 
accumulation in rats (4, 14-18, 20, 23, 26-30, 33, 34). 
1.2 Acute/short term toxicity 
Alachlor is of low to moderate acute oral toxicity with 
LD50-values in rats of 903 to 1350 mg/kg body weight (b.w.). 
It Is an Irritant to skin and mucous membranes and Induces 
skin sensitization in guinea pigs and hyperreactive humans 
(35-44, 50). 
55 
In rather poor 90-day feeding studies In rats and dogs a no-
effect-level (NOEL) of 200 mg/kg feed (10 mg/kg b.w./day) was 
claimed for rats. In dogs a NOEL was not derived because of 
small group sizes and other shortcomings. In a 6-month gavage 
study in dogs, even the lowest dose (5 mg/kg b.w./day) still 
caused changes in liver weight. A NOEL could not be 
establIshed (45-48). 
A 1-year gavage study in dogs resulted, at the highest dose 
level (10 mg/kg b.w./day), in reduced body weight gain, 
changes In liver weight, testicular atrophy, hematology, and 
clinical chemistry. Doses of 3 mg/kg b.w./day and above 
caused hemosiderin deposition in liver, kidneys, and spleen. 
A NOEL of 1 mg/kg b.w./day (lowest dose) can be assumed (49). 
1.3 Effects on reproduction 
Two teratological studies in rabbits gave no Indications of 
teratogenic or foetotoxlc effects at maternal nontoxic dosages 
up to 60 mg/kg b.w./day (43, 79, 132). 
In pregnant rats, dosages of 50 mg/kg b.w./day and above 
during the critical stages of gestation caused maternal 
toxicity. At 150 mg/kg b.w./day foetal weights were reduced 
and resorptions increased (54). 
A three-generation feeding study in rats revealed, even at the 
highest dose (equivalent to 30 mg/kg b.w./day), no significant 
changes except for reduced ovarian weights in all generations 
(43, 55). 
1.4 Long-term toxicity 
An 18-month feeding study in mice with dosages equivalent to 
26, 78 and 260 mg/kg b.w./day showed a high Incidence of 
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amyloidosis In all groups including the controls. Dose-
related Increases In liver weight were observed at the mid and 
high-dose levels. Retinal atrophy and degeneration were 
reported (5% controls; 8% low dose; 8% mid dose; 12% high 
dose). A NOEL cannot be derived from this study (43, 56, 59, 
61). 
Three long-term studies were carried out In rats. In the first 
2-year feeding study in Long-Evans rats, with dietary levels 
equivalent to 14, 42 and 126 mg/kg b.w./day, ophthalmoscopy 
revealed a dose-related uveal degeneration. A NOEL could not 
be established because of a 5% incidence of uveal degeneration 
at the lowest dose level (43, 57). 
In the second study in Long-Evans rats, with a dose level 
equivalent to 126 mg/kg b.w./day for up to 2 years, the ocular 
lesions were investigated In detail. The results of the first 
study were confirmed and the lesions shown to be irreversible 
(62). 
In the third 25-month study In Long-Evans rats lower dietary 
alachlor levels, equivalent to 0.5, 2.5, and 15.0 mg/kg 
b.w./day were used. Mortality rates in the control and all 
treatment groups reached 50% at the termination of the study. 
Ocular lesions were not observed. A NOEL of 2,5 mg/kg 
b.w./day for non carcinogenic toxic effects can be derived 
(58). 
1.5 Mutagenicity 
Numerous mutagenicity studies In vitro (with and without 
activation) and In vivo with alachlor gave negative results in 
conventional tests. However, In vivo and In vitro rat 
hepatocyte DNA repair assays were weakly positive. 
Furthermore, some tests with plant systems were positive (3, 
23, 63-66, 68-73, 78, 83-93, 107). 
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Whereas, bile from alachlor treated rats was negative In the 
Ames-Test with the usual Salmonella typhimurium strains, the 
urine produced weak mutagenic responses In TA98 and TA1537 In 
the presence of b -glucuronidase. Furthermore, three rat 
urinary metabolites, clearly not connected with the proposed 
pathway to the suspected carcinogenic benzoiminoquinone, 
proved positive In TA98. There are positive mutagenicity data 
showing that DEA is positive. Mutagenicity data on the 
proposed key metabolite ADEP are unavailable (3, 23, 67, 68, 
75-77, 79-82, 98, 134). 
1.6 Carcinogenicity 
The 18-month chronic/carcinogenicity study In mice (dietary 
levels equivalent to 26, 78 and 260 mg/kg b.w./day) showed a 
dose-related trend of increased incidence of lung bronchiolar-
aIveolar neoplasms in females significant at the highest dose 
level and increased hepatocellular tumours In males 
significant at only the highest dose level. Animals 
sacrificed at the termination of the study revealed that the 
total number of tumours and the number of tumour bearing mice 
increased dose dependently. In mice that died or were 
sacrificed during the study the percentages of tumour bearing 
mice and of total tumours were enhanced at the high dose but 
reduced at the mid-dose levels. High mortality ( > 50%) was 
observed in this study in all groups (including controls) due 
probably to a high incidence of anmyloldosls In many of the 
test animals. Since only lung and liver tumours were found in 
mice which are common in this species, and despite the 
shortcomings of this study there Is not sufficient evidence to 
conclude that alachlor is carcinogenic In mice (29, 56, 59, 
61). 
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The first chronic/carcinogenic 2-year study in rats was 
carried out with feed levels equivalent to 14, 42 and 126 
mg/kg b.w./day over two years. Nasal turbinate tumours 
(mainly adenoma) were dose-related in the mid and high-dose 
groups and in each of these, three ependymomas (brain tumours) 
were found showing pathological signs, Indicating metastases 
of nasal adenocarcinomas. In addition, the incidence of 
malignant stomach tumours and thyroid follicular tumours was 
increased at the highest dose level. From the weight loss 
reported, it may be concluded that the highest dose level 
exceeded the maximum tolerated dose (MTD) (43, 57, 94). 
The second chronic/carcinogenic 2-year rat study with dose 
levels equivalent to 0.5, 2.5 and 15.0 mg/kg b.w./day revealed 
an increased incidence of nasal epithelial adenoma at the 
highest dose level. However, an increase in the incidence of 
stomach, thyroid and brain tumours was not found (58). 
In the third chronic rat study, not designed as a carcinogenic 
study, a single dose level was used (equivalent to 126 mg/kg 
b.w./day for up to two years). In one subgroup which received 
alachlor for 5 to 5.5 months, an Increased incidence of nasal 
turbinate adenomas in both sexes was observed at study 
termination. Another subgroup which received alachlor during 
the whole study period showed, in addition, elevated 
incidences of adenocarcinomas of the nasal turbinate, 
malignant tumours of the stomach (carcinoma/sarcoma) and 
neoplasms of the thyroid (follicular adenoma + carcinoma, C-
cell adenoma) (58, 62). 
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1.7 Human data ­ occupational exposure 
Dermal deposition data for a lach lor operators showed 
considerable variations independent of formulation used or 
operator function. The possible exposure of the spray 
operator (with an 80% protection) using 4.4 kg alachlor active 
Ingredient (A.l.)/ha (emulsifiable concentrate (EC) was 
calculated to be in the order of 2 χ 10 ­ 2 mg/kg/day on the 
day of application. The rate of application was nearly double 
the generally recommended dosage. Such exposure should result 
In a life­time average exposure of 3 χ 10~5 mg/kg/day or 1 χ 
"IO­3 mg/kg/day, assuming alachlor application on 1 or 30 
days per year respectively. Exposure using other formulations 
would be slightly less; for example, the possible exposure of 
a spray operator on the day of application using micro­
encapsulated alachlor at the rate 4.4 kg a.I./ha was 
calculated to be 9 χ 10~3 mg/kg/day (53, 96, 97). 
Urinary excretion of alachlor and its metabolites containing 
DEA and HEEA moieties ranged between 0 and 132 
ug/person/applIcation day (mean 41.5 ug) per kg alachlor 
applied. As a result of the low excretion level, a detailed 
characterisation of the metabolites was not possible (53, 95). 
The calculated dermal absorption levels ranged from 0.37 to 
11.4% for micro­encapsulated alachlor and from 12.5 to 25% for 
the emulsifiable concentrate preparation (96, 97, 130, 133). 
Vital status follow­up of plant workers exposed to alachlor^ 
for up to 12 years gave no indications that cancer deaths were 
related to exposure. Ocular lesions were no more evident in 
the exposed than in the control individuals (60, 99). 
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2. FATE IN PLANTS 
The metabolism of alachlor In plants Is well understood. The 
parent compound and some of Its microbial soil metabolites may 
be taken up from treated soils and translocated In plants. 
The main metabolic pathways appear to be via: 
- complete displacement of the alachlor chlorine moiety by 
oxygen or sulphur nucleophiles; 
- hydroxylation at the benzyl position; 
- sugar conjugation. 
Considerable quantitative differences between plant species 
were found. Residue determination should Include the parent 
compound and metabolites containing the diethylaniI Ine (DEA) 
and hydroxyethyl-ethylaniI ine (HEEA) moieties. Residues 
resulting from registered uses can be expected generally not 
to exceed 0.21 mg/kg in soybeans and 0.016 mg/kg in maize. 
There Is no evidence for the production of the suspected 
animal carcinogens DEA and ADEP in plants (1, 3, 100-103). 
3. FATE IN DOMESTIC ANIMALS 
Studies by oral administration of 1 4C labelled alachlor to 
laying-hens and goats showed that the major part of alachlor 
and Its metabolites was excreted rapidly. In hens about 90% 
was eliminated at the end of the dosing period (6 days) and 
only 0,07% of the administered radioactlvty was detected In 
eggs, 0,03% in livers and 0,02% in other tissues (51, 52). 
In lactat ing goats dosed for 5 days, 81% of the administered 
dose was excreted rapidly via urine and faeces (42,3 and 30,7% 
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respectively), whilst milk and each of the tissues analysed 
(muscle, liver, kidney and fat) contained, at the end of the 
dosing period, less than 0,5% of the administered 
radioactivity (104, 105). 
Based on these studies it may be concluded that with current 
usage patterns in the Community, no measurable amounts of 
alachlor or Its metabolites may be expected in meat, milk or 
eggs when treated crops or their wastes are fed at normal 
rations to dairy animals and poultry. 
4. FATE AND EFFECTS IN THE ENVIRONMENT 
4.1 soil 
Degradation of alachlor in soils is due predominantly to 
bacterial and fungal metabolism. It leads to a mixture of 
oxan i lie and sulfonic acids and to benzyl i c hydroxy I at ion and 
formation of diethylaniIine (DEA), respectively. DEA 
Interacts rapidly with humic substances in the soil (106, 108-
111, 112, 113, 121, 139). 
Blot i c degradation under aerobic conditions showed ha If-life 
values between 6 and 25 days dependent on the soil type (108-
110, 121). No build up of parent alachlor In the soil 
following applications at the recommended use rates should be 
expected. 
Application of alachlor to sandy soils poses a risk of 
leaching (106, 121). During leaching extensive metabolic 
degradation mainly to oxanilic, sulfonic and sulfonylacet Ic 
conjugates takes place (108, 116, 121). 
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Considerable volatilization can be expected especially In 
moist soils, at higher temperatures and In windy conditions, 
leading possibly to a seasonal contamination of precipitation 
(114, 115, 121, 138). 
4.2 Water 
Occasional contamination of groundwater has been observed with 
alachlor levels of up to 16.6 ug/l (53, 117, 119, 136). 
Degradation of alachlor itself in groundwater and the 
mineralization in surface water are apparently slow (116, 
117). 
Municipal water supplies from rivers In areas with high usage 
of alachlor showed contamination up to 100 ug/l due to run-off 
(128). In tap water, concentrations between 0.22 and 5.1 ug 
a Ι ach lor/1 were sometimes reported following conventional 
surface water treatment without carbon filtration. 
In a monitoring study, conducted by Monsanto (135), little if 
any difference was seen between corresponding raw and finished 
water from 24 community water systems. In this study maximum 
weekly concentrations In finished water were detected up to 
10.9 ug alachlor/1 for the growing season. In a later 
monitoring study up to 9.48 ug alachlor/1 was found in 
finished water (137). Data on degradation products of alachlor 
In raw and drinking water were not available (117, 118, 120, 
121, 131, 135- 137). 
4.3 Ecotoxic effects 
The acute toxicity of alachlor on aquatic indicator organisms 
is low as Judged by the effects of alachlor levels in surface 
water and even from cases of accidental 
63 
spillages. This suggests that the use of alachlor under 
normal conditions does not present environmental risks to 
aquatic life. Available data indicates that acute toxicity to 
the fauna of the agroecosystem Is low. Furthermore, 
bioaccumulation is unimportant. However, long-term 
experimental data are not available for aquatic or 
agroecosystem flora and fauna (115, 122 - 129). 
5. CONCLUSIONS 
Studies with respect to non-care I nogen I c toxic effects of 
alachlor revealed: 
a) low to moderate acute oral toxicity, with 
Irritating and sensitizing effects; 
b) subchronic and chronic toxic effects in mice, rats 
and dogs, comprising increased liver weight and 
species dependent pathological changes In other 
organs. Special noteworthy findings are testicular 
atrophy in dogs, retinal atrophy and degeneration 
in mice and uveal degeneration In rats. It can be 
assumed that the NOEL for non-neoplastic effects is 
1 mg/kg b.w./day In dogs and 2,5 mg/kg b.w./day in 
rats. 
The studies with respect to teratogenic, mutagenic and 
carcinogenic effects of alachlor showed: 
a) There are no indications that alachlor affects 
reproductive functions or causes terata In pups; 
b) Alachlor itself is not mutagenic, although Its 
metabolite DEA has been shown to be mutagenic. 
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c) Alachlor Is clearly carcinogenic In rats causing 
mainly nasal turbinate tumours. Its carcinogenic 
effects are thought to be related to Its 
metabolites, especially DEA, ADEP and 
benzo Im i noqu i none. 
d) There is not sufficient evidence that alachlor Is 
carcinogenic in mice. However, in this context It 
must be noted that the mouse study shows certain 
inadequacies. Therefore, species specificity for 
rats cannot be proven. 
Data on metabolites in laboratory animals show that there are 
considerable differences in metabolism between rats, mice and 
monkeys. The possible carcinogenic metabolites are mainly 
formed in rats but also in low amounts in mice and monkeys. 
Furthermore, it appears from autoradiographic studies that 
alachlor derived material in rats is concentrated in the nasal 
turbinates - this Is not found in either mice or monkeys. 
The species differences in the pharmacokinetics of alachlor 
give a reasonable explanation for the high susceptibility of 
rats to the carcinogenic effects of alachlor. However, they 
cannot exclude its carcinogenicity to other species, e.g. 
mice, monkeys and humans. It has to be assumed that the 
species differences are quantitative rather than qualitative. 
The metabolism of alachlor in plants is well understood. The 
parent compound and some of its soil metabolites may be taken 
up from treated soils and are translocated through the entire 
plant. Residue data for alachlor (Including Its metabolites 
containing DEA and HEAA moieties) is desirable for food crops 
for which alachlor is authorised in the Community (eg beans, 
potatoes). In view of the current usage pattern in the 
Community, dietary exposure from plant sources may be 
considered low. 
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No measurable amounts of aIachlor or its metabolites may be 
expected in meat, milk or eggs, following recommended pre-
emergence use of aIachIor on crops fed to domestic animals. 
Therefore, dietary exposure is low from these sources. 
Since exposure of the general population, via food of plant 
and animal origin and drinking water is low, the margin of 
safety with respect to the suspected carcinogenicity for the 
general population is currently regarded as sufficient. 
In comparison with the general population, operators are 
exposed to a greater extent to a I ach lor. However, considering 
the demonstrated species quantitative differences and provided 
that precautions are taken to minimize exposure, the margin of 
safety for operators with respect to the suspected 
carcinogenicity is regarded as sufficient. 
Application of alachlor to sandy soils poses a risk of 
leaching and thereby also of contamination of groundwater. 
Contamination of surface waters is mostly due to run-off from 
treated soils. Therefore, appropriate precautions should be 
taken to minimize run-off of alachlor and its use in soil 
conditions favourable to leaching should be avoided. 
Data on degradation of alachlor in raw water are required. 
Toxic effects of alachlor to aquatic and terresterial fauna 
are not likely to occur under normal conditions of use. 
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